Open Access

MEG3 is a prognostic factor for CRC and promotes chemosensitivity by enhancing oxaliplatin-induced cell apoptosis

  • Authors:
    • Lixia Li
    • Jian Shang
    • Yupeng Zhang
    • Shi Liu
    • Yanan Peng
    • Zhou Zhou
    • Huaqing Pan
    • Xiaobing Wang
    • Lipng Chen
    • Qiu Zhao
  • View Affiliations

  • Published online on: July 17, 2017     https://doi.org/10.3892/or.2017.5828
  • Pages: 1383-1392
  • Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

A major reason for the failure of advanced colorectal cancer (CRC) treatment is the occurrence of chemoresistance to oxaliplatin-based chemotherapy. Recently, studies have shown that long non-coding RNAs (lncRNAs) play an important role in drug resistance. Using HiSeq sequencing methods, we identified that lncRNAs show differential expression levels in oxaliplatin-resistant (OxR) and non-resistant CRC patients. RT-qPCR was then performed in tissues and serum samples, and lncRNA MEG3 was verified to be downregulated in non-responding patients and to have considerable discriminating potential to identify responding patients from non-responding patients. Moreover, decreased serum MEG3 expression was associated with poor chemoresponse and low survival rate in CRC patients receiving oxaliplatin treatment. Subsequently, OxR cell lines were established, and MEG3 was significantly downregulated in HT29 OxR and SW480 OxR cells. In addition, overexpression of MEG3 with pMEG3 reversed oxaliplatin resistance in both CRC cell lines. Flow cytometric apoptosis analysis indicated that MEG3 promoted CRC cell apoptosis. More importantly, MEG3 enhanced oxaliplatin‑induced cell cytotoxicity in CRC. In conclusion, our integrated approach demonstrated that decreased expression of lncRNA MEG3 in CRC confers potent poor therapeutic efficacy, and that MEG3 promotes chemosensitivity by enhancing oxaliplatin-induced cell apoptosis. Thus, overexpression of MEG3 may be a future direction by which to develop a novel therapeutic strategy to overcome oxaliplatin resistance of CRC patients.
View Figures
View References

Related Articles

Journal Cover

September-2017
Volume 38 Issue 3

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Li L, Shang J, Zhang Y, Liu S, Peng Y, Zhou Z, Pan H, Wang X, Chen L, Zhao Q, Zhao Q, et al: MEG3 is a prognostic factor for CRC and promotes chemosensitivity by enhancing oxaliplatin-induced cell apoptosis. Oncol Rep 38: 1383-1392, 2017
APA
Li, L., Shang, J., Zhang, Y., Liu, S., Peng, Y., Zhou, Z. ... Zhao, Q. (2017). MEG3 is a prognostic factor for CRC and promotes chemosensitivity by enhancing oxaliplatin-induced cell apoptosis. Oncology Reports, 38, 1383-1392. https://doi.org/10.3892/or.2017.5828
MLA
Li, L., Shang, J., Zhang, Y., Liu, S., Peng, Y., Zhou, Z., Pan, H., Wang, X., Chen, L., Zhao, Q."MEG3 is a prognostic factor for CRC and promotes chemosensitivity by enhancing oxaliplatin-induced cell apoptosis". Oncology Reports 38.3 (2017): 1383-1392.
Chicago
Li, L., Shang, J., Zhang, Y., Liu, S., Peng, Y., Zhou, Z., Pan, H., Wang, X., Chen, L., Zhao, Q."MEG3 is a prognostic factor for CRC and promotes chemosensitivity by enhancing oxaliplatin-induced cell apoptosis". Oncology Reports 38, no. 3 (2017): 1383-1392. https://doi.org/10.3892/or.2017.5828